Chikungunya is a viral disease primarily transmitted through the bite of infected mosquitoes. With at least 5 million reported cases in the past 15 years, it poses a significant global health threat. The highest risk areas are tropical and subtropical regions of Africa, Southeast Asia, and parts of the Americas. However, the virus has expanded to new regions, increasing its global prevalence.
Chikungunya is most commonly found in tropical and subtropical regions. High-risk areas include countries in Africa (Kenya, Tanzania, Madagascar), Southeast Asia (India, Thailand, Indonesia, Malaysia, the Philippines, Myanmar), the Pacific Islands (Fiji, Samoa, Solomon Islands), the Americas (Puerto Rico, the Dominican Republic, Haiti, Costa Rica, El Salvador, Nicaragua, Brazil, Colombia, Venezuela), and Southern Europe (Italy, France, Spain). When traveling to these regions, take preventive measures against mosquito bites and consider getting vaccinated with Ixchiq for added protection.
Common Symptoms:
Some individuals may experience debilitating joint pain that can persist for months or years.
Treatment:
What is Ixchiq? Ixchiq is a vaccine approved to prevent chikungunya virus infection. It is administered as a single dose via injection into the muscle and contains a live, weakened version of the chikungunya virus.
Ixchiq represents a significant advancement in the prevention of Chikungunya, addressing a crucial unmet medical need. Continued research and monitoring will ensure its safety and effectiveness as it becomes more widely available.